Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04055844 · ClinicalTrials.gov registry record · Phase 2
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
A Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 3
- Study locations
NCT04055844 is a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 14 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT04055844, a Phase 2 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
Conditions Studied
Interventions
- DRUG Decitabine
- DRUG Ruxolitinib
- DRUG Donor Lymphocyte Infusion (DLI)
Study Locations (3)
Minnesota
- Masonic Cancer Center, University of Minnesota - Minneapolis
Missouri
- Washington University Medical School - St Louis
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2022-09-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04055844
The ClinicalTrials.gov registry entry for NCT04055844 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (88% lower). The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Decitabine is the first listed.
NCT04055844 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT04055844 about?
NCT04055844 is a clinical study titled "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS". This is a multi-center, single-arm, open-label, phase II trial for the frontline treatment of relapsed AML or MDS following allo-HCT. Eligible subjects will receive up to 4 cycles of combined modality treatment. The number of cycles depends on response, toxicity, and the remaining cell dose.
What is the current status of trial NCT04055844?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2020-02-17. Estimated completion is 2022-09-06.
What conditions does trial NCT04055844 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloid and Monocytic Leukemia.
What interventions are being tested in trial NCT04055844?
The interventions under investigation include: Decitabine (DRUG), Ruxolitinib (DRUG), Donor Lymphocyte Infusion (DLI) (DRUG).
Who is sponsoring clinical trial NCT04055844?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04055844 being conducted?
This trial has 3 study locations across Minnesota, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.